Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week, Clinical Study Designed to Assess the Efficacy and Safety of BDP Nasal Aerosol (80 mcg, Once Daily) in Pediatric Subjects (4 to 11 Years of Age) With PAR
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs Beclometasone (Primary)
- Indications Perennial allergic rhinitis
- Focus Registrational; Therapeutic Use
- Sponsors Teva Pharmaceutical Industries
- 23 Feb 2015 Results presented at the 2015 Annual Meeting of the American Academy of Allergy, Asthma and Immunology, according to Teva Pharmaceutical Industries media release.
- 30 Oct 2014 According to the Teva Pharmaceutical Industries pipeline, company plans to submit a supplemental NDA to the FDA based on results from this study by the end of 2014.
- 01 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.